Pharmaceuticals
Antengene Announces First Patient Dosed in the Phase I/II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas
SHANGHAI and HONG KONG, May 23, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer...
2022-05-23 10:10
4013
Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma
-- European Commission Decision Anticipated within Approximately 60 Days -- NEWTON, Mass. and FLORENCE, Italy, May 21, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini")...
2022-05-21 01:19
11275
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
* Emerald study met both its primary end points of Progression-free survival (PFS) in overall population and in ESR1 mutated patients * PFS rate at 12 months with elacestrant was 22.32% vs. 9.42% with SOC in the overall population, and 26.76% vs. 8.19% in theESR1 mutation population * Data d...
2022-05-20 16:17
4843
Lipidor updates on Phase III study of AKP02 in treatment of psoriasis - half of patients now recruited
STOCKHOLM, May 20, 2022 /PRNewswire/ -- Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that half of the patients have now been enrolled in the Phase III study of AKP02 skin spray for mild to moderate psoriasis, with the last patient expected to begin treatment inJune 2022. T...
2022-05-20 14:56
3324
Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit
GAITHERSBURG, Md. and SUZHOU, China, May 20, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Company's Executive Director and Chief Medical O...
2022-05-20 12:31
4721
CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing
TIANJIN, China, May 19, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that the World Health Organization ("WHO") has granted Emergency Use Listing ("EUL") for Convidecia™, CanSinoBIO's Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5...
2022-05-19 23:28
4983
Berry Oncology Launches an Innovative Self-Iterative "HIFI" System
BEIJING, May 18, 2022 /PRNewswire/ -- Berry Oncology, a leading company in the global industry for genetic testing and early screening of tumors, recently launched a HIFI system. The HIFI system consists of HIFI-det liquid biopsy technology and the corresponding HIFI-cal series of algorithms. W...
2022-05-19 09:00
3239
PostEra spearheads AI-driven drug discovery collaboration to develop antiviral therapeutics with initial $68M in NIH funding
BOSTON, May 19, 2022 /PRNewswire/ -- PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced a multi-year collaboration with the National Institutes of Health to develop small molecule antiviral therapeutics to prevent pandemics. The cente...
2022-05-19 04:56
5225
BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement
VANCOUVER, BC, May 18, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV; FRA: 5LB; OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that Hospices Civils deLyon, France ("HCL") has agreed to serve as a clinical study site for the Phase I study of BVX-0918, the Company's autologous ...
2022-05-18 20:00
5334
Antengene Announces XPOVIO® Treatment Regimens Included for the First Time in the Guidelines for the Diagnosis and Management of Multiple Myeloma in China
SHANGHAI and HONG KONG, May 18, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hema...
2022-05-18 15:01
4174
SIMCERE PHARMA (HK.2096) Novel Inhibitor of COVID-19 3CLpro SIM0417 Received a Second Clinical Trial Approval in China
HONG KONG, May 18, 2022 /PRNewswire/ -- SIMCERE PHARMA (HK.2096) announced that SIM0417, a candidate drug against SARS-Cov-2, for which the Company holds license from Shanghai Institute ofMateria Medica (SIMM) and Wuhan Institute of Virology, Chinese Academy of Sciences, has obtained the Clinica...
2022-05-18 11:56
3010
Sinclair Pharma Partners with Vanguard Aesthetics to Launch Silhouette Soft in Malaysia
Equipped with the world's only cone technology for optimal lift, Silhouette
Soft provides longer lasting results.
KUALA LUMPUR, Malaysia, May 18, 2022 /PRNewswire/ -- Sinclair Pharma
2022-05-18 09:01
4949
ASEAN accepts mutually recognized COVID-19 vaccination certificates
DENPASAR, Indonesia, May 17, 2022 /PRNewswire/ -- ASEAN Member States collectively recognize the COVID-19 vaccination certificate to be applied in Southeast Asia. Health Ministers of ASEAN countries endorsed the decision during the 15th ASEAN Health Ministers Meeting (15th AHMM) inNusa Dua, Bali, ...
2022-05-17 19:14
3138
ABL AND ODIMMA THERAPEUTICS JOIN FORCES IN PERSONALIZED CANCER IMMUNOTHERAPY
PARIS, May 17, 2022 /PRNewswire/ -- ABL Europe (ABL
2022-05-17 15:00
4343
CStone announces final PFS analysis of a registrational study of sugemalimab in patients with stage III NSCLC further demonstrates its robust efficacy and significant clinical benefits shown in interim analysis
* Sugemalimab is the world's first anti-PD-(L)1 monoclonal antibody to significantly improve progression-free survival (PFS) in patients with stage III non-small cell lung cancer (NSCLC) without disease progression following concurrent or sequential chemoradiotherapy * The National Medical Pr...
2022-05-17 08:02
4261
Ascletis (1672.HK) Included in MSCI China Small Cap Index
HANGZHOU and SHAOXING, China, May 16, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it will be included in the MSCI China Small Cap Index, effective after the market close onMay 31, 2022. Morgan Stanley Capital International (MSCI) is a leading provider o...
2022-05-16 20:17
5761
Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China
-Distribution channels in place to streamline/facilitate patient access. -XPOVIO® will be available in 600 hospitals and 105 DTPs (across China includingBeijing, Shanghai, Guangdong, Jiangsu, Zhejiang, Henan, and Shandong). SHANGHAI and HONG KONG, May 16, 2022 /PRNewswire/ -- Antengene Corporatio...
2022-05-16 11:20
4283
Innovent Will Present Clinical Data of IBI110 (anti-LAG-3 monoclonal antibody) and Other Multiple Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
SAN FRANCISCO and SUZHOU, China, May 16, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and ...
2022-05-16 08:00
4779
Seegene reports first quarter 2022 financial results
* Q1 revenue up 10% QoQ to reach record quarterly high of KRW 451.5 billion * Foundation for sales expansion strengthened through '3 Ct' technology commercialization, Allplex™ RV Master Assay approval, increased PCR instrument sales * "Seegene to secure future growth by targeting syndromic t...
2022-05-13 19:00
3499
Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress
SHANGHAI and HONG KONG, May 13, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hema...
2022-05-13 18:00
4193
Week's Top Stories
Most Reposted
DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 277 media titles]
2026-10-06 05:28Zenika CTO Adrien Nortain Moves Base to Singapore to Strengthen Technical Leadership in Asia
[Picked up by 271 media titles]
2026-10-01 10:00
ViewSonic Launches VG1457 Dual-Screen Portable Monitor for Productivity Anywhere
[Picked up by 269 media titles]
2026-09-30 10:50
Sunway University to Host Asia's First Global Tipping Points Conference 2026
[Picked up by 263 media titles]
2026-09-30 12:11
Vestas Powers Up Vietnam's Clean Energy Ambitions with Two New Projects Under PDP8 Totaling 16 Wind Turbines
[Picked up by 263 media titles]
2026-10-02 16:27
Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
23861
